Comprehensive Stock Comparison
Compare PMGC Holdings Inc. (ELAB) vs BiomX Inc. (PHGE) vs Armata Pharmaceuticals, Inc. (ARMP) vs Seres Therapeutics, Inc. (MCRB) vs Evogene Ltd. (EVGN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  MCRB | 448.4% revenue growth vs ARMP's 14.2% |
| Quality / Margins | MCRB | 15.4% net margin vs ARMP's -9.3% |
| Stability / Safety |  ARMP | Beta 0.21 vs ELAB's 1.74 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | ARMP | +474.8% vs ELAB's -96.5% |
| Efficiency (ROA) | MCRB | 3.8% ROA vs PHGE's -142.8%, ROIC -180.9% vs -305.2% |
Who Each Stock Is For
Income & stability
ARMPDividend streak 0 yrs, beta 0.21
Growth exposure
ELABRev growth 44.1%, EPS growth 86.0%, 3Y rev CAGR 13.4%
Long-term compounding (10Y)
ARMP-98.0% 10Y total return vs MCRB's -98.5%
Sleep-well-at-night portfolio
PHGELower volatility, beta 0.93, Low D/E 39.7%, current ratio 2.48x
Defensive / Recession hedge
EVGNBeta 0.54, current ratio 1.15x
Business Model
What each company does and how it makes money
PMGC Holdings is a biopharmaceutical company developing novel aesthetic medicines and therapeutic products, with a focus on engineered probiotics for muscle preservation during weight loss treatments. It generates revenue primarily through research and development activities, investment operations, and potential future commercialization of its lead product EL-22 — a first-in-class probiotic targeting obesity-related muscle loss. The company's competitive advantage lies in its proprietary engineered probiotic technology platform addressing an emerging need in the rapidly growing GLP-1 weight loss market.
BiomX is a clinical-stage biotechnology company developing targeted phage therapies — viruses that kill specific harmful bacteria — for chronic diseases and skin conditions. It generates no commercial revenue yet but is funded through equity offerings and partnerships to advance its pipeline, which includes therapies for cystic fibrosis, inflammatory bowel diseases, and atopic dermatitis. The company's key advantage is its proprietary platform for discovering and engineering natural phages that precisely target disease-causing bacteria while sparing beneficial microbes.
Armata Pharmaceuticals is a clinical-stage biotech company developing targeted bacteriophage therapies to treat antibiotic-resistant bacterial infections. It generates revenue primarily through research collaborations and partnerships — like its Merck deal — while advancing its pipeline of phage-based candidates through clinical trials. The company's key advantage is its proprietary bacteriophage platform technology, which offers a novel approach to targeting specific drug-resistant pathogens.
Seres Therapeutics is a microbiome therapeutics company developing bacterial consortia treatments for serious diseases. It generates revenue primarily through collaboration agreements and milestone payments — notably with Nestlé Health Science — while advancing its lead candidate SER-109 toward FDA approval for recurrent C. difficile infection. The company's key advantage is its proprietary platform for rationally designing bacterial consortia that functionally interact with human biology, creating a technical moat in the emerging microbiome therapeutics field.
Evogene is a computational biology company that uses its proprietary AI-powered platform to discover and develop products across agriculture, human health, and industrial applications. It generates revenue through research collaborations, licensing agreements, and milestone payments from partners—primarily in agriculture (~70% of focus) and human health (~30%). The company's key advantage is its Computational Predictive Biology platform, which leverages big data and machine learning to accelerate product discovery in life sciences with higher precision than traditional methods.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 5 stocks. BestLagging
Financial Scorecard
ELAB 3ARMP 2PHGE 0MCRB 0EVGN 0ELAB4/6 metricsELAB2/3 metricsELAB3/9 metricsARMP5/6 metricsARMP2/2 metricsELAB leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). ARMP leads in 2 (Total Returns, Risk & Volatility).
Financial Metrics (TTM)
EVGN and ELAB operate at a comparable scale, with $5M and -$1M in trailing revenue. MCRB is the more profitable business, keeping 15.4% of every revenue dollar as net income compared to ARMP's -9.3%. On growth, ELAB holds the edge at -45.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ELABPMGC Holdings Inc. | PHGEBiomX Inc. | ARMPArmata Pharmaceut… | MCRBSeres Therapeutic… | EVGNEvogene Ltd. |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | -$1M | $0 | $5M | $351,000 | $5M |
| EBITDAEarnings before interest/tax | -$4M | -$6M | -$32M | -$99M | -$13M |
| Net IncomeAfter-tax profit | -$7M | -$37M | -$47M | $5M | -$3M |
| Free Cash FlowCash after capex | -$7M | -$28M | -$27M | -$23M | -$17M |
| Gross MarginGross profit ÷ Revenue | +72.8% | — | +70.5% | -50.1% | +16.1% |
| Operating MarginEBIT ÷ Revenue | -75.7% | — | -6.6% | -294.7% | -2.8% |
| Net MarginNet income ÷ Revenue | -2.5% | — | -9.3% | +15.4% | -52.3% |
| FCF MarginFCF ÷ Revenue | -2.2% | — | -5.4% | -66.6% | -3.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -45.8% | — | -61.0% | — | -82.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +100.0% | -6.5% | -3.9% | +112.3% | +133.6% |
Valuation Metrics
| Metric | ELABPMGC Holdings Inc. | PHGEBiomX Inc. | ARMPArmata Pharmaceut… | MCRBSeres Therapeutic… | EVGNEvogene Ltd. |
|---|---|---|---|---|---|
| Market CapShares × price | $23,875 | $82.8B | $420M | $80M | $7M |
| Enterprise ValueMkt cap + debt − cash | -$4M | $82.8B | $537M | $141M | $5M |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -4.29x | -22.19x | -0.48x | -0.29x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.01x | — | 81.14x | — | 0.86x |
| Price / BookPrice ÷ Book value/share | 0.00x | 3427.64x | — | 5.15x | 0.32x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
Profitability & Efficiency
MCRB delivers a 12.3% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-4 for PHGE. PHGE carries lower financial leverage with a 0.40x debt-to-equity ratio, signaling a more conservative balance sheet compared to MCRB's 6.65x. On the Piotroski fundamental quality scale (0–9), ELAB scores 4/9 vs MCRB's 2/9, reflecting mixed financial health.
| Metric | ELABPMGC Holdings Inc. | PHGEBiomX Inc. | ARMPArmata Pharmaceut… | MCRBSeres Therapeutic… | EVGNEvogene Ltd. |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -78.4% | -3.6% | — | +12.3% | -15.9% |
| ROA (TTM)Return on assets | -44.6% | -142.8% | -52.4% | +3.8% | -10.5% |
| ROICReturn on invested capital | -82.7% | -3.1% | -44.2% | -180.9% | -102.4% |
| ROCEReturn on capital employed | -33.7% | -159.9% | -70.7% | -67.7% | -66.5% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 | 2 | 2 | 3 |
| Debt / EquityFinancial leverage | — | 0.40x | — | 6.65x | 0.87x |
| Net DebtTotal debt minus cash | -$4M | -$8M | $117M | $61M | -$2M |
| Cash & Equiv.Liquid assets | $4M | $18M | $9M | $31M | $15M |
| Total DebtShort + long-term debt | $0 | $10M | $127M | $92M | $13M |
| Interest CoverageEBIT ÷ Interest expense | -17.68x | -36.86x | -2.12x | — | -4.42x |
Total Returns (with DRIP)
A $10,000 investment in ARMP five years ago would be worth $25,857 today (with dividends reinvested), compared to $1 for ELAB. Over the past 12 months, ARMP leads with a +474.8% total return vs ELAB's -96.5%. The 3-year compound annual growth rate (CAGR) favors ARMP at 56.0% vs ELAB's -96.0% — a key indicator of consistent wealth creation.
| Metric | ELABPMGC Holdings Inc. | PHGEBiomX Inc. | ARMPArmata Pharmaceut… | MCRBSeres Therapeutic… | EVGNEvogene Ltd. |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -26.1% | +194.4% | +77.0% | -39.7% | -25.8% |
| 1-Year ReturnPast 12 months | -96.5% | -48.8% | +474.8% | -40.3% | -40.6% |
| 3-Year ReturnCumulative with dividends | -100.0% | -93.2% | +279.4% | -91.7% | -88.8% |
| 5-Year ReturnCumulative with dividends | -100.0% | -99.5% | +158.6% | -97.6% | -98.2% |
| 10-Year ReturnCumulative with dividends | -100.0% | -99.7% | -98.0% | -98.5% | -98.8% |
| CAGR (3Y)Annualised 3-year return | -96.0% | -59.1% | +56.0% | -56.4% | -51.8% |
Risk & Volatility
ARMP is the less volatile stock with a 0.21 beta — it tends to amplify market swings less than ELAB's 1.74 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ARMP currently trades 71.1% from its 52-week high vs ELAB's 3.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ELABPMGC Holdings Inc. | PHGEBiomX Inc. | ARMPArmata Pharmaceut… | MCRBSeres Therapeutic… | EVGNEvogene Ltd. |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.74x | 0.93x | 0.21x | 1.21x | 0.54x |
| 52-Week HighHighest price in past year | $30.50 | $14.71 | $16.34 | $29.98 | $2.42 |
| 52-Week LowLowest price in past year | $1.01 | $1.56 | $0.90 | $6.53 | $0.81 |
| % of 52W HighCurrent price vs 52-week peak | +3.4% | +42.8% | +71.1% | +30.5% | +34.6% |
| RSI (14)Momentum oscillator 0–100 | 16.2 | 51.0 | 71.9 | 32.0 | 36.0 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 1.3M | 50K | 70K | 547K |
Analyst Outlook
Analyst consensus: ARMP as "Buy", MCRB as "Buy". Consensus price targets imply -22.5% upside for ARMP (target: $9) vs -86.3% for MCRB (target: $1).
| Metric | ELABPMGC Holdings Inc. | PHGEBiomX Inc. | ARMPArmata Pharmaceut… | MCRBSeres Therapeutic… | EVGNEvogene Ltd. |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Buy | — |
| Price TargetConsensus 12-month target | — | — | $9.00 | $1.25 | — |
| # AnalystsCovering analysts | — | — | 4 | 18 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 0 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Nov 23 | Mar 26 | Change |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | 100 | 0.01 | -100.0% |
| BiomX Inc. (PHGE) | 100 | 8.71 | -91.3% |
| Armata Pharmaceutic… (ARMP) | 100 | 481.86 | +381.9% |
| Seres Therapeutics,… (MCRB) | 100 | 41.87 | -58.1% |
| Evogene Ltd. (EVGN) | 100 | 12.5 | -87.5% |
Armata Pharmaceutic… (ARMP) returned +159% over 5 years vs PMGC Holdings Inc. (ELAB)'s -100%. A $10,000 investment in ARMP 5 years ago would be worth $25,857 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | $0.00 | $2M | — |
| BiomX Inc. (PHGE) | $0.00 | $0.00 | — |
| Armata Pharmaceutic… (ARMP) | $475000.00 | $5M | +989.3% |
| Seres Therapeutics,… (MCRB) | $0.00 | $0.00 | — |
| Evogene Ltd. (EVGN) | $11M | $9M | -23.5% |
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | -948.9% | -2.5% | +99.7% |
| Armata Pharmaceutic… (ARMP) | -108.6% | -3.7% | +96.6% |
| Seres Therapeutics,… (MCRB) | -4.2% | -45.2% | -975.5% |
| Evogene Ltd. (EVGN) | -154.7% | -193.7% | -25.2% |
Armata Pharmaceuticals, Inc.'s net margin went from -109% (2015) to -4% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | -0.08 | -274.68 | -332442.4% |
| BiomX Inc. (PHGE) | -3.27 | -1.47 | +55.0% |
| Armata Pharmaceutic… (ARMP) | -278.6 | -0.52 | +99.8% |
| Seres Therapeutics,… (MCRB) | -46.6 | -18.86 | +59.5% |
| Evogene Ltd. (EVGN) | -0.68 | -2.89 | -325.0% |
Chart 5Free Cash Flow — 5 Years
PMGC Holdings Inc. generated $-5M FCF in 2024 (-691% vs 2021). BiomX Inc. generated $-37M FCF in 2024 (-18% vs 2021).
ELAB vs PHGE vs ARMP vs MCRB vs EVGN: Key Questions Answered
7 questions · data-driven answers · updated daily
01Is ELAB or PHGE or ARMP or MCRB or EVGN a better buy right now?
Analysts rate Armata Pharmaceuticals, Inc. (ARMP) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ELAB or PHGE or ARMP or MCRB or EVGN?
Over the past 5 years, Armata Pharmaceuticals, Inc. (ARMP) delivered a total return of +158.6%, compared to -100.0% for PMGC Holdings Inc. (ELAB). A $10,000 investment in ARMP five years ago would be worth approximately $26K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ARMP returned -98.0% versus ELAB's -100.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ELAB or PHGE or ARMP or MCRB or EVGN?
By beta (market sensitivity over 5 years), Armata Pharmaceuticals, Inc. (ARMP) is the lower-risk stock at 0.21β versus PMGC Holdings Inc.'s 1.74β — meaning ELAB is approximately 717% more volatile than ARMP relative to the S&P 500. On balance sheet safety, BiomX Inc. (PHGE) carries a lower debt/equity ratio of 40% versus 7% for Seres Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — ELAB or PHGE or ARMP or MCRB or EVGN?
Seres Therapeutics, Inc. (MCRB) is the more profitable company, earning 1537% net margin versus -365.6% for Armata Pharmaceuticals, Inc. — meaning it keeps 1537% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PHGE leads at 0.0% versus -294.7% for MCRB. At the gross margin level — before operating expenses — ELAB leads at 72.8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — ELAB or PHGE or ARMP or MCRB or EVGN?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is ELAB or PHGE or ARMP or MCRB or EVGN better for a retirement portfolio?
For long-horizon retirement investors, Armata Pharmaceuticals, Inc. (ARMP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.21)). PMGC Holdings Inc. (ELAB) carries a higher beta of 1.74 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ARMP: -98.0%, ELAB: -100.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between ELAB and PHGE and ARMP and MCRB and EVGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.